Diabetic patients taking GLP-1s may face increased risk of eye disease, study suggests

Diabetic patients taking GLP-1s may face increased risk of eye disease, study suggests

Drugs like Ozempic and Mounjaro linked to macular degeneration, but researchers note limitations

Diabetes is the leading cause of vision loss in people between 18 and 64 years old, according to the American Diabetes Association. (iStock)

Glucagon-like peptide-1 receptor agonists (GLP-1s) have been linked to a higher risk of eye disease. (iStock)

Researchers found that the participants taking GLP-1s had twice the risk of developing neovascular age-related macular degeneration (nAMD) compared to people not taking them. (iStock)

The incidence of nAMD in the general population is about one in 1,000, and it doubled to two in 1,000 for the group taking the GLP-1s in the study. (iStock)